Welcome to our dedicated page for Abpro Holdings SEC filings (Ticker: ABPWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Abpro Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Abpro Holdings's regulatory disclosures and financial reporting.
Abpro Holdings, Inc. (ABPO) announced that Chief Executive Officer Miles Suk voluntarily resigned from the CEO role effective August 19, 2026, while remaining on the Board of Directors. The Board appointed M. Fatih Karatas, 47, as Interim Chief Executive Officer, effective August 25, 2026. The company states Mr. Suk’s resignation was not due to any disagreement regarding operations, policies, or practices.
Mr. Karatas brings over 20 years of experience in global finance and investment management, including leadership roles at AIS Advisors, SAASPASS, QInvest, and UBS AG overseeing portfolios exceeding $130 billion. He will serve as interim CEO without compensation for three months, after which a compensation arrangement may be considered. In connection with his resignation as CEO, Mr. Suk’s consulting agreement was terminated, and he is entitled to continued pro-rata payments of his $300,000 annual consulting fee for 60 days, totaling approximately $50,000.
Abpro Holdings, Inc. reported for the quarter ended June 30, 2026 that it remains a development-stage biotech with no product revenue and a continued net loss. Net loss was $0.9 million for the quarter and $2.0 million for the first six months of 2026, compared with losses of $3.0 million and $6.9 million in the prior-year periods, reflecting sharply reduced research and development spending.
Cash increased to $4.2 million at June 30, 2026, largely from $7.3 million of proceeds from issuing 3.16 million shares under a Standby Equity Purchase Agreement, but current liabilities of $8.2 million left a total stockholders’ deficit of $3.0 million. Management states there is substantial doubt about the company’s ability to continue as a going concern within one year without additional capital. During the period, Abpro’s shares were delisted from Nasdaq and moved to the OTC Pink Limited Market, which the company notes may adversely affect liquidity and future fund-raising.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of Shares of Common Stock of ABPRO HOLDINGS INC in an amended Schedule 13G filing. The filing states that the Goldman entities have shared voting and dispositive power over 180,690 shares, representing 3.0% of the class, and no sole voting or dispositive power.
The securities are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC, a registered broker-dealer and investment adviser and a subsidiary of The Goldman Sachs Group, Inc. The reporting group notes it is reporting ownership of 5 percent or less of ABPRO’s common stock and includes standard disclaimers that certain Goldman Sachs operating units and client or fund accounts may beneficially own securities separately from the reporting units.
Abpro Holdings, Inc. received notice from the Nasdaq Listing and Hearing Review Council that it reaffirmed a prior decision to delist the company’s securities from Nasdaq. The Council cited Abpro’s failure to meet the minimum equity standard under Nasdaq Listing Rule 5550(b)(1) by the February 16, 2026 deadline set in a November 10, 2025 panel decision.
Abpro expects Nasdaq to file a Form 25 to delist and deregister its securities under Section 12(b) of the Exchange Act. The company expects its common stock and public warrants to continue quotation on the OTC Pink Market under the symbols “ABP” and “ABPWW,” but warns holders about potentially limited information availability, reduced transparency and liquidity, and greater trading volatility.
Abpro Holdings, Inc. reported a smaller net loss of $1,028 thousand for the quarter ended March 31, 2026, compared with $3,887 thousand a year earlier, as operating expenses fell sharply to $933 thousand from $2,958 thousand.
Cash rose to $5,398 thousand and total assets to $6,865 thousand, mainly from issuing 3,162,785 shares under its Standby Equity Purchase Agreement for gross proceeds of $7,264 thousand. Despite this, current liabilities of $9,117 thousand and a stockholders’ deficit of $2,252 thousand leave the company with negative equity.
Management states there is substantial doubt about Abpro’s ability to continue as a going concern within one year without additional financing. Its common stock was delisted from Nasdaq effective February 23, 2026 and now trades on the OTC Pink Limited market under “ABPO,” which may further hinder capital-raising efforts.
Abpro Holdings, Inc. is an early-stage biotechnology company developing next‑generation multispecific antibody drugs for cancer and eye diseases, built on its DiversImmune and TetraBi platforms. The company completed a reverse recapitalization with SPAC Atlantic Coastal Acquisition Corp. II in November 2024 and effected a 1‑for‑30 reverse stock split effective October 31, 2025.
Abpro’s lead oncology asset ABP‑102, partnered worldwide with Celltrion, received FDA clearance of its IND on January 6, 2026, enabling a Phase 1 trial in HER2‑positive solid tumors. Ophthalmology candidate ABP‑201 is licensed regionally to Abpro Bio, with additional T‑cell engager programs ABP‑110 and ABP‑150 in pre‑clinical development.
The business is highly capital constrained. Management discloses substantial doubt about its ability to continue as a going concern and relies on external financing. A $50 million Standby Equity Purchase Agreement with YA II PN, Ltd. funded approximately $1.0 million in 2025 and $6.7 million of net proceeds in early 2026, but became unavailable after Abpro’s common stock was delisted from Nasdaq on February 23, 2026 and moved to the OTC Pink Limited Market. As of June 30, 2025, non‑affiliate market value was about $9.3 million, and 5,896,048 common shares were outstanding as of March 30, 2026.
Abpro Holdings, Inc. reported that Nasdaq has notified the company it is no longer in compliance with several board and committee independence listing rules following the recent resignations of two independent directors, creating additional bases for potential delisting from The Nasdaq Capital Market.
Nasdaq cited noncompliance with rules requiring a majority-independent board, a three-member independent audit committee, and a two-member independent compensation committee. Abpro must present its views to a Nasdaq Hearings Panel by February 12, 2026, and has a cure period for the compensation committee extending to certain future shareholder meeting dates.
On February 9, 2026, Abpro appointed M. Fatih Karatas and Mary Gunn as Class II directors and to the audit, compensation, and nominating and corporate governance committees, aiming to address the independence and composition deficiencies. The company notes there is no immediate impact on the listing of its common stock or warrants, but there is no assurance it will regain full compliance or that the Panel will grant continued listing.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have disclosed a passive ownership stake in Abpro Holdings Inc. They report beneficial ownership of 196,537 shares of Abpro common stock, representing 6.8% of the outstanding class, as of the event date of 12/31/2025.
All 196,537 shares are reported with shared voting and shared dispositive power, and no sole voting or dispositive authority. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Abpro.
Abpro Holdings, Inc. reported that two members of its Board of Directors, Anthony D. Eisenberg and Sooyoung Lee, have resigned from the board and all related committees. Both resignations were effective in late January 2026 and were explicitly stated as not arising from any disagreement with the company, its board, or its management on operations, policies, or practices.
Following these departures, the Board has begun a process to identify and appoint new qualified independent directors to fill the vacancies and to meet applicable Nasdaq Stock Market requirements within the time periods allowed by the Nasdaq Listing Rules.